Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review

被引：1
|
作者：
Onishi, Shumpei [1 ,2 ,3 ]
Ohba, Shinji [1 ,2 ]
Kuraoka, Kazuya [2 ,4 ]
Kurashige, Takashi [2 ,5 ]
Sugiyama, Kazuhiko [6 ,7 ]
Yamasaki, Fumiyuki [3 ]
机构：
[1] Natl Hosp Org Kure Med Ctr, Dept Neurosurg, Hiroshima, Japan
[2] Chugoku Canc Ctr, Hiroshima, Japan
[3] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan
[4] Natl Hosp Org Kure Med Ctr, Dept Diagnost Pathol, Hiroshima, Japan
[5] Natl Hosp Org Kure Med Ctr, Dept Neurol, Hiroshima, Japan
[6] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan
[7] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima, Japan
来源：
NEUROCIRUGIA | 2022年 / 33卷 / 06期
关键词：
Glioblastoma; H3K27M-mutation; Non-midline;
D O I：
10.1016/j.neucie.2021.06.008
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
The WHO classification of tumors of the CNS in 2016 defined "diffuse midline glioma, H3 K27M-mutant" as a new tumor entity locating in the CNS midline. However, the H3 K27M-mutation in "non-midline" glioblastoma are rare and their characteristics have been rarely reported. A 16-year-old girl presented a hyper-intense lesion at her left temporal stem on T2WI, FLAIR and DWI. Biopsy was performed and molecular pathological diagnosis was glioblastoma with H3 K27M-mutant. Accordingly, the possibility of H3 K27M-mutant should be examined not only for diffuse glioma without IDH mutation that develops at a midline location, but also in non-midline locations. (c) 2021 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码：356 / 360
页数：5
相关论文
共 18 条
  • [1] Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
    Banan, Rouzbeh
    Christians, Arne
    Bartels, Stephan
    Lehmann, Ulrich
    Hartmann, Christian
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2017, 5
  • [2] Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma
    Lopez, Giselle
    Bush, Nancy Ann Oberheim
    Berger, Mitchel S.
    Perry, Arie
    Solomon, David A.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2017, 5 : 38
  • [3] H3K27M-mutant glioma in thoracic spinal cord and conus medullaris with pilocytic astrocytoma morphology: case report and review of the literature
    Palpan Flores, Alexis
    Rodriguez Dominguez, Victor
    Esteban Rodriguez, Isabel
    Roman de Aragon, Maria
    Zamarron Perez, Alvaro
    BRITISH JOURNAL OF NEUROSURGERY, 2024, 38 (04) : 1020 - 1026
  • [4] Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation
    Aboian, M. S.
    Solomon, D. A.
    Felton, E.
    Mabray, M. C.
    Villanueva-Meyer, J. E.
    Mueller, S.
    Cha, S.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2017, 38 (04) : 795 - 800
  • [5] Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review
    De Martino, Lucia
    Picariello, Stefania
    Russo, Carmela
    Errico, Maria Elena
    Spennato, Pietro
    Papa, Maria Rosaria
    Normanno, Nicola
    Scimone, Giuseppe
    Colafati, Giovanna Stefania
    Cacchione, Antonella
    Mastronuzzi, Angela
    Massimino, Maura
    Cinalli, Giuseppe
    Quaglietta, Lucia
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2023, 16
  • [6] Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review
    Lasocki, Arian
    Abdalla, Gehad
    Chow, Geoffrey
    Thust, Stefanie C.
    CANCER IMAGING, 2022, 22 (01)
  • [7] A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults
    Ekhator, Chukwuyem
    Rak, Ramin
    Tadipatri, Ramya
    Fonkem, Ekokobe
    Grewal, Jai
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [8] Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M — a case report
    Hanna Gött
    Silke Kiez
    Hildegard Dohmen
    Malgorzata Kolodziej
    Marco Stein
    Child's Nervous System, 2022, 38 : 1791 - 1796
  • [9] Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M-a case report
    Goett, Hanna
    Kiez, Silke
    Dohmen, Hildegard
    Kolodziej, Malgorzata
    Stein, Marco
    CHILDS NERVOUS SYSTEM, 2022, 38 (09) : 1791 - 1796
  • [10] MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
    Abe, Hideaki
    Natsumeda, Manabu
    Kanemaru, Yu
    Watanabe, Jun
    Tsukamoto, Yoshihiro
    Okada, Masayasu
    Yoshimura, Junichi
    Oishi, Makoto
    Fujii, Yukihiko
    NEUROLOGIA MEDICO-CHIRURGICA, 2018, 58 (07) : 290 - 295
12